Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature
- 1 January 2021
- journal article
- research article
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 15 (1) , 159-167
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Activation of the GLP-1 Receptor by Liraglutide Increases ACE2 Expression, Reversing Right Ventricle Hypertrophy, and Improving the Production of SP-A and SP-B in the Lungs of Type 1 Diabetes RatsEndocrinology, 2015
- Pioglitazone attenuates lung injury by modulating adipose inflammationJournal of Surgical Research, 2014
- Metformin inhibits hepatitis B virus protein production and replication in human hepatoma cellsJournal of Viral Hepatitis, 2013
- Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMCNature, 2013
- Sitagliptin Exerts an Antinflammatory ActionThe Journal of Clinical Endocrinology & Metabolism, 2012
- Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: systematic review and meta-analysisThorax, 2011
- Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa‐2a plus ribavirin†‡Hepatology, 2009
- Pioglitazone Inhibits the Expression of Inflammatory Cytokines From Both Monocytes and Lymphocytes in Patients With Impaired Glucose ToleranceArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophyEuropean Journal of Pharmacology, 2006
- Effects of Sulfonylurea Compounds on Pneumocystis cariniiThe Journal of Infectious Diseases, 1986